
Injectable, Structural Regenerative Implant for Cartilage Care
Protect • Repair • Regenerate
Cartilage injuries can turn simple movement into a challenge. Without timely treatment, damage may progress and increase the risk of arthritis or future joint replacement.
At Liquid Cartilage, our goal isjoint preservation and regeneration—not replacement. WithChondroFiller®, we deliver advanced, evidence-led care on Harley Street.

Cartilage provides the smooth, low-friction surface that lets your joints move comfortably. It doesn’t readily self-repair, but with the right scaffold and biological cues,regeneration is possible.
Act early to preserve more of what you have.

ChondroFiller® is an acellular,biologic collagen scaffold delivered in liquid form. Once placed, itgels within minutes, filling the defect and providing a framework that invites your cells to rebuild cartilage.
Think of it like “epoxy” for cartilage—without the plastic.
One treatment. One step. A chance to keep your joint for the long term.


ChondroFiller® sits in a different class—structural regenerative implant.
| Treatment | Analogy | What it Does | Limitation |
|---|---|---|---|
| HA (Hyaluronic Acid) | WD-40 | Improves lubrication for short-term comfort | Temporary; does not regenerate tissue |
| Arthrosamid® | Silicone | Acts on the synovium to reduce pain signalling | Not regenerative; literature notes complication rates up to 30% |
| ChondroFiller® | Epoxy resin | Fills defects, stabilises, and promotes true cartilage repair | Most robust injectable option for structural repair |
ChondroFiller®: our structural, regenerative approach to focal cartilage defects.
Small joints: thumb, fingers, elbow, AC joint, toes, TMJ…
From £2,100
Large joints: knee, hip, shoulder, ankle
From £2,800
Best for knee, hip, shoulder
From £6,500 (knee), £9,500 (hip/shoulder)
Our proprietary MSC Co-Delivery Technique
Introductory offer: your consultation fee is credited toward treatment if you proceed.

Quick, no-obligation chat

Comprehensive assessment with Prof. Paul Lee

Injection, Keyhole, or Liquid Cartilage™

Precise and minimally invasive



Cartilage damage won’t reverse on its own—yet with the right plan it can beprotected, repaired, and regenerated.
At Liquid Cartilage, you access world-leading science and a joint-preservation vision on Harley Street.
(Consultation fee credited towards treatment if you proceed.)
Everything you want to know about ChondroFiller® at Liquid Cartilage.
ChondroFiller® is an acellular collagen gel that fills cartilage defects and forms a scaffold for your own cells to regenerate healthy tissue. Unlike temporary injections, it supports hyaline-like restorationfor smoother motion and protection long-term.
HA or Arthrosamid® may give short-term pain relief, while ChondroFiller® aims to rebuild cartilage. Compared with replacement, it preserves your natural joint and avoids prosthesis risks. Our approach is regenerate-first.
Studies show +30 IKDC in knees,+33 Harris Hip Score in hips, and improved ankle metrics. MRI (MOCART) typically reads 70–87. Globally,>19,000 cases support safety and function.
Best for focal defects up to 6 cm² in knees, hips, ankles, or small joints. Active younger patients often benefit, but older patients may qualify if surrounding cartilage is stable.
Delivered via precise injection orkeyhole surgery. The gel sets in minutes. Expectpartial weight-bearing ~6 weeks, steady return to cycling/swimming, and most sports around~12 months alongside specialist rehab.
Harley Street location; UK ICRS Centre of Excellence. Led byProf. Paul Lee, with advanced options likeLiquid Cartilage™ (ChondroFiller® + cells) to prioritise preservation.
Discover what makes ChondroFiller® unique at Liquid Cartilage.

Whether knee osteochondritis dissecans requires surgery or heals with conservative care depends chiefly on skeletal maturity: stable juvenile lesions achieve healing in roughly 52–67% of cases, whilst spontaneous healing is uncommon in adults and surgery is typically necessary.

ChondroFiller injection and ACI/MACI produce comparable functional improvement for focal cartilage defects, but reoperation rates diverge sharply—3–8% versus up to 37%—a gap unresolved by head-to-head clinical comparison.

ChondroFiller injection, an acellular collagen scaffold, gels at patellar cartilage defects and recruits the patient's own progenitor cells to repair the tissue—without penetrating bone or producing the fibrocartilage that microfracture generates and that deteriorates within two to three years.

Focal cartilage damage on the talar dome — lesions no larger than 1.2 cm² with defined borders — is treated with ChondroFiller, a Type I collagen scaffold that polymerises in an outpatient clinic and recruits the ankle's own repair cells.

Competitive athletes undergoing OATS showed 14% failure at ten years versus 38% for microfracture—a gap appearing between years five and ten as fibrocartilage repair tissue progressively degrades under athletic loading.

Lesion area in square centimetres, not depth grade, is the single most influential variable determining knee cartilage treatment: under 2 cm² conservative care, 2–4 cm² mixed surgical options, over 4 cm² structural grafting.